Last updated: July 17, 2026

Application No. 17/825,875

COVALENT RAS INHIBITORS AND USES THEREOF

Final Rejection

Filed

May 26, 2022

Priority

Nov 27, 2019 — provisional 62/940,947 +3 more

Examiner

MARTIN, KEVIN STEPHEN

Art Unit

1626

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Revolution Medicines Inc.

OA Round

2 (Final)

Interview Optional

— +24.5% interview lift. Examiner has a relatively high allowance rate (75%); +24.5% interview lift. A written response may suffice.

Based on 146 resolved cases, 2023–2026

Examiner Intelligence

MARTIN, KEVIN STEPHEN View full profile →

Grants 75% — above average

Career Allowance Rate

110 granted / 146 resolved

+15.3% vs TC avg

Strong +24% interview lift

Without

With

+24.5%

Interview Lift

resolved cases with interview

Typical timeline

3y 5m

Avg Prosecution

43 currently pending

Career history

179

Total Applications

across all art units

Statute-Specific Performance

§101

0.3%

-39.7% vs TC avg

§103

34.8%

-5.2% vs TC avg

§102

14.5%

-25.5% vs TC avg

§112

36.8%

-3.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 146 resolved cases

Prosecution Timeline

May 26, 2022

Application Filed

Aug 13, 2025

Non-Final Rejection mailed

Nov 13, 2025

Response Filed

Jun 25, 2026

Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/421,921

Patent 12678431

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS

5y 0m to grant Granted Jul 14, 2026

18/007,641

Patent 12679833

N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS

3y 7m to grant Granted Jul 14, 2026

18/023,696

Patent 12673106

MODULATORS OF NUCLEAR RECEPTOR SUBFAMILY 4 GROUP A MEMBER 1 (NR4A1) AND USES THEREOF

3y 4m to grant Granted Jul 07, 2026

17/413,991

Patent 12667552

DIETARY BUTYRATE

5y 0m to grant Granted Jun 30, 2026

17/883,743

Patent 12662465

EGFR INHIBITORS

3y 10m to grant Granted Jun 23, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4

Expected OA Rounds

75%

Grant Probability

99%

With Interview (+24.5%)

3y 5m (~0m remaining)

Median Time to Grant

Moderate

PTA Risk

Based on 146 resolved cases by this examiner. Grant probability derived from career allowance rate.